Related Experiment Video
Updated: Jul 7, 2025
Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA
Published on: February 23, 2024
Identification of promising small-molecule inhibitors targeting STK17B for cancer therapeutics: molecular docking and
Modinat Wuraola Akinboade1, Abel Ujaigbe Egbemhenghe2, Teslim Oluwaseyi Abdulkareem3
1Department of Biochemistry, Ladoke Akintola University of Technology, Ogbomosho, Oyo State, Nigeria.
Abstract:
Cancer is a complex disease characterized by the uncontrolled growth of abnormal cells, leading to the formation of tumours. STK17B, a member of the DAPK family, has been implicated in various cancers and is considered a potential therapeutic target. However, no drug in the market has been approved for the treatment of STK17 B-associated cancer disease. This research aimed to identify direct inhibitors of STK17B using computational techniques. Ligand-based virtual screening and molecular docking were performed, resulting in the selection of three lead compounds (CID_135698391, CID_135453100, CID_136599608) with superior binding affinities compared to the reference compound dovitinib. While molecular docking simulation revealed specific interactions between the lead compounds and key amino acid residues at the binding pocket of STK17B, molecular dynamics simulations demonstrated that CID_135453100 and CID_136599608 exhibit stable conformations and comparable flexibility to dovitinib. However, CID_135698391 did not perform well using this metric as it displayed poor stability. Overall, small-molecule compounds CID_135453100 and CID_136599608 showed promising binding interactions and stability, suggesting their potential as direct inhibitors of STK17B. These findings could contribute to the exploration of novel therapeutic options targeting STK17B in cancer treatment.
Insights
Researchers identified potential new cancer drugs targeting STK17B using computational methods. Two compounds, CID_135453100 and CID_136599608, show promise as STK17B inhibitors for cancer therapy.
Area of Science:
- Oncology
- Computational Chemistry
- Drug Discovery
Background:
- Cancer is characterized by uncontrolled cell growth, with STK17B implicated in various cancers.
- STK17B is a potential therapeutic target, but no approved drugs currently exist for STK17B-associated cancers.
- Developing targeted therapies for STK17B is crucial for advancing cancer treatment.
Purpose of the Study:
- To identify direct small-molecule inhibitors of STK17B using computational approaches.
- To evaluate the binding affinity and stability of potential STK17B inhibitors.
- To provide a foundation for novel therapeutic strategies against STK17B-driven cancers.
Main Methods:
- Ligand-based virtual screening and molecular docking were employed to identify lead compounds.
- Binding affinities of selected compounds were compared against the reference drug dovitinib.
- Molecular dynamics simulations assessed the stability and conformational flexibility of lead compounds.
Main Results:
- Three lead compounds (CID_135698391, CID_135453100, CID_136599608) demonstrated superior binding affinities to STK17B compared to dovitinib.
- Molecular docking revealed specific interactions between lead compounds and STK17B binding pocket residues.
- CID_135453100 and CID_136599608 exhibited stable conformations and comparable flexibility to dovitinib, unlike CID_135698391.
Conclusions:
- Small-molecule compounds CID_135453100 and CID_136599608 show significant potential as direct STK17B inhibitors.
- These compounds exhibit promising binding interactions and stability, warranting further investigation.
- The findings support the development of novel therapeutic agents targeting STK17B for cancer treatment.
More Related Videos
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
10:20Method for Identifying Small Molecule Inhibitors of the Protein-protein Interaction Between HCN1 and TRIP8b
Published on: November 11, 2016
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:15Drugs that Stabilize Microtubules